Darbepoetin Alfa Disappoints in RED-HFDarbepoetin Alfa Disappoints in RED-HF

Sponsors for the RED-HF trial say no new safety concerns arose with the drug, but treatment had no benefit over placebo in terms of reducing death from any cause or first hospital admission for worsening HF in patients with left ventricular systolic dysfunction and anemia. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news